Celgene (CELG) EPS & PE Ratio History
Current and historical earning per share (EPS) and price to earnings (PE) ratio for Celgene (CELG) over the last 10 years. The current PE ratio for Celgene as of March 16, 2018 is 13.06.
|Medical||Medical - Biomedical and Genetics||$67.402B||$13.003B|
|Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.|